Wyeth 3Q Revenues: $5.6 billion (+9%) 3Q Earnings: $1.1 billion (flat) YTD Revenues: $16.6 billion (+10%) YTD Earnings: $3.6 billion (+8%) Comments: 3Q pharma revenues were up 10% to $4.7 billion, driven by a 24% boost in sales of Prevnar vaccine to $634 million and a 39% rise in ex-NA sales of Enbrel to $527 million. Top-seller Effexor posted a 4% increasse to $958 million. Earnings were impaired by a $117 million charge related to Wyeth’s ongoing restructuring....